Fundamental Analysis of SAVARA INC(NASDAQ:SVRA) stock

Fundamental Rating

Taking everything into account, SVRA scores 2 out of 10 in our fundamental rating. SVRA was compared to 568 industry peers in the Biotechnology industry. The financial health of SVRA is average, but there are quite some concerns on its profitability. SVRA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

SVRA had negative earnings in the past year.

SVRA had a negative operating cash flow in the past year.

SVRA had negative earnings in each of the past 5 years.

SVRA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SVRA has a Return On Assets of -34.73%. This is in the better half of the industry: SVRA outperforms 63.19% of its industry peers.

The Return On Equity of SVRA (-41.60%) is better than 72.04% of its industry peers.

		Industry Rank	Sector Rank
ROA	-34.73%
ROE	-41.6%
ROIC	N/A

ROA(3y)-27.48%

ROA(5y)-38.13%

ROE(3y)-34.71%

ROE(5y)-51.61%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SVRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, SVRA has more shares outstanding

The number of shares outstanding for SVRA has been increased compared to 5 years ago.

The debt/assets ratio for SVRA has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 5.56 indicates that SVRA is not in any danger for bankruptcy at the moment.

SVRA has a Altman-Z score of 5.56. This is amongst the best in the industry. SVRA outperforms 81.77% of its industry peers.

SVRA has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.

SVRA has a worse Debt to Equity ratio (0.13) than 66.37% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.13
Debt/FCF	N/A
Altman-Z	5.56

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 17.70 indicates that SVRA has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 17.70, SVRA belongs to the top of the industry, outperforming 92.92% of the companies in the same industry.

SVRA has a Quick Ratio of 17.70. This indicates that SVRA is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of SVRA (17.70) is better than 92.92% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	17.7
Quick Ratio	17.7

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SVRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.71%.

EPS 1Y (TTM)-38.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-10%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

SVRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.81% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-40.95%

EPS Next 2Y-17.41%

EPS Next 3Y10.55%

EPS Next 5Y22.81%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SVRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SVRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-17.41%

EPS Next 3Y10.55%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SVRA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SAVARA INC

NASDAQ:SVRA (12/20/2024, 8:00:00 PM)

After market: 3.23 0 (0%)

3.23

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)N/A N/A

Inst Owners93.82%

Inst Owner Change8.53%

Ins Owners19.12%

Ins Owner Change0.47%

Market Cap554.33M

Analysts86.15

Price Target9.98 (208.98%)

Short Float %7.78%

Short Ratio8.01

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-4.08%

Min EPS beat(2)-8.6%

Max EPS beat(2)0.45%

EPS beat(4)2

Avg EPS beat(4)-1.16%

Min EPS beat(4)-11.37%

Max EPS beat(4)14.89%

EPS beat(8)5

Avg EPS beat(8)-2.76%

EPS beat(12)7

Avg EPS beat(12)0.93%

EPS beat(16)9

Avg EPS beat(16)-6.83%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-9.27%

PT rev (3m)-9.27%

EPS NQ rev (1m)-16.19%

EPS NQ rev (3m)-16.19%

EPS NY rev (1m)-2.47%

EPS NY rev (3m)-2.47%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.78
P/tB	2.94
EV/EBITDA	N/A

EPS(TTM)-0.43

EYN/A

EPS(NY)-0.45

Fwd EYN/A

FCF(TTM)-0.47

FCFYN/A

OCF(TTM)-0.47

OCFYN/A

SpS0

BVpS1.16

TBVpS1.1

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-34.73%
ROE	-41.6%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-27.48%

ROA(5y)-38.13%

ROE(3y)-34.71%

ROE(5y)-51.61%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.13
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	47.2%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	17.7
Quick Ratio	17.7
Altman-Z	5.56

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)153.1%

Cap/Depr(5y)347.91%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-38.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-10%

EPS Next Y-40.95%

EPS Next 2Y-17.41%

EPS Next 3Y10.55%

EPS Next 5Y22.81%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-68.36%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year19.99%

EBIT Next 3Y27.97%

EBIT Next 5YN/A

FCF growth 1Y-130.72%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-130.88%

OCF growth 3YN/A

OCF growth 5YN/A

SAVARA INC (SVRA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens